Cargando…

Expression of HLA Class I and HLA Class II by Tumor Cells in Chinese Classical Hodgkin Lymphoma Patients

BACKGROUND: In Caucasian populations, the tumor cells of Epstein Barr virus (EBV)-positive classical Hodgkin Lymphomas (cHL) patients more frequently express HLA class I and HLA class II molecules compared to EBV-negative cHL patients. HLA expression (in relation to EBV) in Asian cHL patients has no...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Xin, van den Berg, Anke, Gao, Zifen, Visser, Lydia, Nolte, Ilja, Vos, Hans, Hepkema, Bouke, Kooistra, Wierd, Poppema, Sibrand, Diepstra, Arjan
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2878318/
https://www.ncbi.nlm.nih.gov/pubmed/20526359
http://dx.doi.org/10.1371/journal.pone.0010865
_version_ 1782181852642017280
author Huang, Xin
van den Berg, Anke
Gao, Zifen
Visser, Lydia
Nolte, Ilja
Vos, Hans
Hepkema, Bouke
Kooistra, Wierd
Poppema, Sibrand
Diepstra, Arjan
author_facet Huang, Xin
van den Berg, Anke
Gao, Zifen
Visser, Lydia
Nolte, Ilja
Vos, Hans
Hepkema, Bouke
Kooistra, Wierd
Poppema, Sibrand
Diepstra, Arjan
author_sort Huang, Xin
collection PubMed
description BACKGROUND: In Caucasian populations, the tumor cells of Epstein Barr virus (EBV)-positive classical Hodgkin Lymphomas (cHL) patients more frequently express HLA class I and HLA class II molecules compared to EBV-negative cHL patients. HLA expression (in relation to EBV) in Asian cHL patients has not been previously investigated. METHODOLOGY/PRINCIPAL FINDINGS: We randomly selected 145 cHL patients with formalin-fixed, paraffin embedded tissue blocks available from 5 hospitals from the Northern part of China. Hematoxylin & Eosin-stained slides were used to reclassify the histological subtypes according to the WHO classification. EBV status was determined by visualization of EBERs in tumor cells using in situ hybridization. Membranous expression of HLA molecules was detected by immunohistochemistry using antibodies HC-10 (class I heavy chain) and anti-ß2-microglobulin for HLA class I, and CR3/43 for HLA class II. EBV+ tumor cells were observed in 40% (58/145) of the cHL patients. As expected, the percentage of EBV+ cases was much higher in the mixed cellularity subtype (71%) than in the nodular sclerosis subtype (16%) (p<0.001). Expression of HLA class I was observed in 79% of the EBV+ cHL cases and in 30% of the EBV- cases (p<0.001). For HLA class II, 52% of EBV+ cHL cases were positive, compared to 43% in EBV- cases (p = 0.28). CONCLUSIONS: The results in the Northern China population were similar to those in the Caucasian population for HLA class I, but not for HLA class II.
format Text
id pubmed-2878318
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-28783182010-06-04 Expression of HLA Class I and HLA Class II by Tumor Cells in Chinese Classical Hodgkin Lymphoma Patients Huang, Xin van den Berg, Anke Gao, Zifen Visser, Lydia Nolte, Ilja Vos, Hans Hepkema, Bouke Kooistra, Wierd Poppema, Sibrand Diepstra, Arjan PLoS One Research Article BACKGROUND: In Caucasian populations, the tumor cells of Epstein Barr virus (EBV)-positive classical Hodgkin Lymphomas (cHL) patients more frequently express HLA class I and HLA class II molecules compared to EBV-negative cHL patients. HLA expression (in relation to EBV) in Asian cHL patients has not been previously investigated. METHODOLOGY/PRINCIPAL FINDINGS: We randomly selected 145 cHL patients with formalin-fixed, paraffin embedded tissue blocks available from 5 hospitals from the Northern part of China. Hematoxylin & Eosin-stained slides were used to reclassify the histological subtypes according to the WHO classification. EBV status was determined by visualization of EBERs in tumor cells using in situ hybridization. Membranous expression of HLA molecules was detected by immunohistochemistry using antibodies HC-10 (class I heavy chain) and anti-ß2-microglobulin for HLA class I, and CR3/43 for HLA class II. EBV+ tumor cells were observed in 40% (58/145) of the cHL patients. As expected, the percentage of EBV+ cases was much higher in the mixed cellularity subtype (71%) than in the nodular sclerosis subtype (16%) (p<0.001). Expression of HLA class I was observed in 79% of the EBV+ cHL cases and in 30% of the EBV- cases (p<0.001). For HLA class II, 52% of EBV+ cHL cases were positive, compared to 43% in EBV- cases (p = 0.28). CONCLUSIONS: The results in the Northern China population were similar to those in the Caucasian population for HLA class I, but not for HLA class II. Public Library of Science 2010-05-28 /pmc/articles/PMC2878318/ /pubmed/20526359 http://dx.doi.org/10.1371/journal.pone.0010865 Text en Huang et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Huang, Xin
van den Berg, Anke
Gao, Zifen
Visser, Lydia
Nolte, Ilja
Vos, Hans
Hepkema, Bouke
Kooistra, Wierd
Poppema, Sibrand
Diepstra, Arjan
Expression of HLA Class I and HLA Class II by Tumor Cells in Chinese Classical Hodgkin Lymphoma Patients
title Expression of HLA Class I and HLA Class II by Tumor Cells in Chinese Classical Hodgkin Lymphoma Patients
title_full Expression of HLA Class I and HLA Class II by Tumor Cells in Chinese Classical Hodgkin Lymphoma Patients
title_fullStr Expression of HLA Class I and HLA Class II by Tumor Cells in Chinese Classical Hodgkin Lymphoma Patients
title_full_unstemmed Expression of HLA Class I and HLA Class II by Tumor Cells in Chinese Classical Hodgkin Lymphoma Patients
title_short Expression of HLA Class I and HLA Class II by Tumor Cells in Chinese Classical Hodgkin Lymphoma Patients
title_sort expression of hla class i and hla class ii by tumor cells in chinese classical hodgkin lymphoma patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2878318/
https://www.ncbi.nlm.nih.gov/pubmed/20526359
http://dx.doi.org/10.1371/journal.pone.0010865
work_keys_str_mv AT huangxin expressionofhlaclassiandhlaclassiibytumorcellsinchineseclassicalhodgkinlymphomapatients
AT vandenberganke expressionofhlaclassiandhlaclassiibytumorcellsinchineseclassicalhodgkinlymphomapatients
AT gaozifen expressionofhlaclassiandhlaclassiibytumorcellsinchineseclassicalhodgkinlymphomapatients
AT visserlydia expressionofhlaclassiandhlaclassiibytumorcellsinchineseclassicalhodgkinlymphomapatients
AT nolteilja expressionofhlaclassiandhlaclassiibytumorcellsinchineseclassicalhodgkinlymphomapatients
AT voshans expressionofhlaclassiandhlaclassiibytumorcellsinchineseclassicalhodgkinlymphomapatients
AT hepkemabouke expressionofhlaclassiandhlaclassiibytumorcellsinchineseclassicalhodgkinlymphomapatients
AT kooistrawierd expressionofhlaclassiandhlaclassiibytumorcellsinchineseclassicalhodgkinlymphomapatients
AT poppemasibrand expressionofhlaclassiandhlaclassiibytumorcellsinchineseclassicalhodgkinlymphomapatients
AT diepstraarjan expressionofhlaclassiandhlaclassiibytumorcellsinchineseclassicalhodgkinlymphomapatients